Clinical Characterization of Symptomatic Populations

Ametropia Clinical Trial

Official title:

Clinical Characterization of Symptomatic Populations

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03319212
• Other study ID #: CR-5969
• Status: Completed
• Phase: N/A
• Start date: September 29, 2017
• Est. completion date: August 15, 2018

Study information

• Verified date: October 2019
• Source: Johnson & Johnson Vision Care, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an unmasked, non-randomized, single arm, stratified, dispensing investigation of symptomatic and asymptomatic subject populations. Subjects will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 105
• Est. completion date: August 15, 2018
• Est. primary completion date: August 15, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Potential subjects must satisfy all of the following criteria to be enrolled in the study:

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.

2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.

3. Between 18 and 55 (inclusive) years of age at the time of screening.

4. Be a current soft contact lens wearer in both eyes with a minimum of 3 days/week wear time over the last 1 month by self-report.

5. Have a baseline CLDEQ-8 score of either:

1. 7 or lower

2. 15 or greater

6. Subjects must possess a functional / usable pair of spectacles and bring them to the visit (only if applicable - to the investigators discretion).

7. Subjects must pass a pre-screening questionnaire.

8. Subjects must be willing to discontinue all contact lens wear for approximately 1 week/

9. Subjects must present to visit 1 with their habitual lenses on eye for at least 6 hours.

Exclusion Criteria:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:

1. Currently pregnant or lactating, by self-report.

2. Any ocular or systemic allergies, disease or use of medication which may interfere with contact lens wear (at the discretion of the investigator).

3. Any active ocular abnormalities/conditions that may interfere with contact lens wear (at the discretion of the investigator).

4. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report.

5. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.

6. Habitual contact lens wear modality as extended wear (=1 night per month of extended wear).

7. Habitual contact lens is rigid gas permeable, toric, monovision or multi-focal

8. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.)

9. Participation in any contact lens or lens care product clinical trial within 2 weeks prior to study enrollment.

10. Employee or employee's immediate family member of clinical site (e.g., Investigator, Coordinator, Technician).

11. Current habitual use of Restasis, Xiidra, ocular steroids, or any medication (RX or OTC) that may interfere with contact lens wear (at the discretion of the investigator).

Related Conditions & MeSH terms

• Ametropia
• Refractive Errors

Intervention

Device:
• senofilcon A contact lenses
Senofilcon A Daily Disposable Contact Lenses

Locations

Country	Name	City	State
Canada	University of Waterloo Center for Contact Lens Research	Waterloo	Ontario
United States	VRC-East	Jacksonville	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Vision Care, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Meibomian Gland Imaging	Meibomian gland imaging was assessed in each each subject eye, at baseline, 4-Week Follow-up (during lens wear) and the the 5-Week Follow-up on subjects' bare eyes. Meibomian gland imaging is expressed interms of area of loss using the following grading scale: Degree 0 ˜ 0%; Degree 1 = 25%; Degree 2 26% - 50%; Degree 3 51% - 75%; Degree 4 = 75%.	4-Week Follow-up
Primary	Meibomian Gland Expressibility	Meibomian glands were assessed in the three regions of each lower eyelid: temporal, central, and nasal. Approximately five glands are expressed per region with each use of the Meibomian Gland Evaluator. Secretions for each of the 5 glands selected within the three regions were graded using the following secretion grading scale: Grade 0 = No Secretion (Includes capped orifices), Grade 1 = Inspissated (semi-solid, toothpaste-like consistency), Grade 2 = Colored/Cloudy Liquid, Grade 3 = Clear Liquid Oil. The total grades for 5 glands per region was calculated for each subject. The total Meibomian Gland Secretion Score was calculated by adding the grades for the 15 glands assessed. Mean and standard deviation for total grade per region and total Meibomian Gland Secretion Score were reported for each stratum. Total scores range from 0 to 15 were lower score indicate worsening meibomian gland expressability.	4-Week Follow-up
Primary	Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings	Lid margin evaluation was conducted for upper and lower lids for both left and right eyes. The presence of the following biomicroscopy findings were recorded as No/normal or Yes/abnormal: Irregularity: Notching of Margin; Vascularity of Lid Margin: Telangiectasia; Meibomian Gland Pouting, Plugging, or Capping; Lid/Lash Margin Debris Findings.; The number of positive findings (yes) was reported for each group.	4-Week Follow-up
Primary	Lid Wiper Epitheliopathy	Horizontal length of staining and sagittal width of staining were graded for both upper and lower lids for each eye. Average grade was calculated separately for upper and lower lids, and the final grade was calculated as the average grade across upper and lower lids. Mean and standard deviation were reported for the final grade by stratum. Subjects were classified according to their final lid wiper epitheliopathy grade for each eye using the following scale: None = 0, Mild = 0.25 - 1.00, Moderate = 1.25 - 2.00, and Severe = 2.25 - 3.00. Final Grades range from 0 to 3, where higher final grades indicate worsening lid wiper epitheliopathy.	4-Week Follow-up
Primary	Conjunctival Folds	Lid-parallel conjunctival folds (LIPCOF) will be evaluated in the area perpendicular to the temporal and nasal limbus on the bulbar conjunctiva above the lower lid (temporal and nasal LIPCOF, respectively), and classified using the LIPCOF grading scale: 0 = No conjunctival folds, 1 = One permanent and clear parallel fold, 2 = Two permanent and clear parallel folds (normally lower than 0.2mm), and 3 = More than two permanent and clear parallel folds (normally higher than 0.2mm).	4-Week Follow-up
Secondary	Conjunctival Redness	Limbal and bulbar conjunctival redness were assessed or each quadrant (nasal, temporal, inferior, superior) using the following scale: 0 = Normal, 1 = Trace, 2 = Mild, 3 = Moderate, and 4 = Severe.	4-Week Follow-up
Secondary	Conjunctival Staining	Conjunctival staining was assessed for each eye by quadrant (Superior, Inferior, Nasal, Temporal) utilizing the following scale: Grade 0 = None (No conjunctival staining), Grade 1 = Trace (Scattered superficial punctate staining), Grade 2 = Mild (Regional or generalized punctate staining), Grade 3 = Moderate (Significant coalesced punctate staining), Grade 4 = Severe (Patch staining).	4-Week Follow-up
Secondary	Corneal Staining	Corneal staining was assessed for each eye by region (Central, Superior, Inferior, Nasal, Temporal). Corneal staining type was evaluated using the following the scale: Grade 0 = None, Grade 1 = Micropunctate, Grade 2 = Macropunctate, Grade 3 = Coalesced Macropunctate, and Grade 4 = Patch (>1mm). Corneal staining area was evaluated using the following the scale: Grade 0 = 0% of region covered, Grade 1 = 10% of region covered, Grade 2 = 20% of region covered, Grade 3 = 30% of region covered, Grade 4 = 40% of region covered, Grade 5 = 50% of region covered, Grade 6 = 60% of region covered, Grade 7 = 70% of region covered, Grade 8 = 80% of region covered, Grade 9 = 90% of region covered, and Grade 10 = 100% of region covered. The following scale was used in the grading of corneal staining depth: Grade 0 = None, Grade 0 = Superficial epithelial, Grade 2 = Full epithelial, and Grade 3 = Stromal glow.	4-Week Follow-up
Secondary	Tear Film Lipid Layer Thickness	Tear film lipid layer thickness was measured for each eye using LipiView II. The Review Lipid Images screen provided numerical analysis of the measured lipid layer thickness in nanometers (nm) from 10 (thinnest) to 240 (thickest), with a precision of 1 nm and an accuracy of 10 nm.	4-Week Follow-up
Secondary	Tear Film Stability	Non-invasive tear break-up time (NIBUT) was measured for each eye to indicate the stability of the tear film. NIBUT is measured as the time interval in seconds after the final blink to the first appearance of distortion in the reflected rings; or to the time that the participant has to blink due to discomfort. Three measurements were taken on each eye. The average NIBUT was reported for each group.	4-Week Follow-up
Secondary	Tear Film Lipid Pattern	Tear film lipid pattern was recorded for each eye using the following categories: None, Open Meshwork, Closed (Tight Meshwork), Flow (Wave), Amorphous, Colors, and Other.	4-Week Follow-up